AlphAIAlphAI — Financial news for AI agents
StockNASDAQ · US · USDHealthcare · Biotechnology

$PHIO

Phio Pharmaceuticals Corp.

Price · $PHIOvia TradingView
AI sentiment · 7d1 articles
OCT 7net (bullish − bearish)OCT 13
Bullish
1
Neutral
0
Bearish
0
Insider · 30dAll trades →
Buys
$31K
5 txs
Sells
—
0 txs
BRADFORD PATRICIA A2× · $19K
10b5-1 share of filings0%
See all $PHIO insider activity →
Top stories · $PHIOMore →
OCT 13·stocktitan.netMed

A cancer drug's first production-scale batch is complete; a clinical study is planned for early 2027.

Phio Pharmaceuticals (PHIO) announced the successful production of its first commercial-scale batch of PH-762, a cancer drug. The batch meets quality standards and will be used in a planned Phase 2b clinical trial set to begin in Q1 2027. The company's CEO highlighted this as a significant milestone, reducing development risks and supporting future clinical and regulatory steps.

SEP 30·SEC EDGAR

Plott Ronald Todd purchased $10K of PHIO

Plott Ronald Todd purchased 10,000 shares of Phio Pharmaceuticals Corp. (PHIO) at an average of $1.04 ($1.03–$1.04) across 2 trades over 2026-09-28 to 2026-09-29.

SEP 28·SEC EDGAR 8-K

Phio Pharmaceuticals Corp. (PHIO): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Phio Pharmaceuticals Corp. (PHIO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Phio Pharmaceuticals Corp. (the “Company”) held its 2026 Annual Meeting of Stockholders via live webcast (the “Annual Meet

PHIO sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning PHIO (Phio Pharmaceuticals Corp.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.

Recent PHIO coverage spans insider activity, corporate actions and financial news.

In the last 30 days, PHIO insiders filed 5 SEC Form 4 transactions — 5 purchases ($31K) and no sales. The most active reporter was BRADFORD PATRICIA A with 2 filings.

What's driving PHIO

AlphAI scores every news story that mentions PHIO with an AI model for sentiment and relevance, and aggregates insider trades from Phio Pharmaceuticals Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $PHIO

Score
OCT 13$PHIOMedAI 8/10stocktitan.net

A cancer drug's first production-scale batch is complete; a clinical study is planned for early 2027.

Phio Pharmaceuticals (PHIO) announced the successful production of its first commercial-scale batch of PH-762, a cancer drug. The batch meets quality standards and will be used in a planned Phase 2b clinical trial set to begin in Q1 2027. The company's CEO highlighted this as a significant milestone, reducing development risks and supporting future clinical and regulatory steps.

2 min read
SEP 28$PHIOLowSEC EDGAR 8-K

Phio Pharmaceuticals Corp. (PHIO): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Phio Pharmaceuticals Corp. (PHIO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Phio Pharmaceuticals Corp. (the “Company”) held its 2026 Annual Meeting of Stockholders via live webcast (the “Annual Meet

1 min read
SEP 14$PHIOMedAI 8/10insidermonkey.com

Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma

Phio Pharmaceuticals (PHIO) submitted a meeting request and briefing package to the FDA for PH-762, its lead clinical compound for cutaneous squamous cell carcinoma. The submission follows the completion of a Phase 1b trial and outlines plans for a Phase 2b study. The company expects to complete final activities for the next clinical phase by Q1 2027.

2 min read
SEP 14$PHIOMedAI 8/10SEC EDGAR 8-K

Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma

Phio Pharmaceuticals Corp. (PHIO) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma Company Proposes Planned Phase 2b Neoadjuvant Study Following Successful Completion of Phase 1b Trial KING OF PR

1 min read

Related tickers

More in Biotechnology